相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity
Estela Gonzalez-Gualda et al.
AGING CELL (2020)
Cytotoxicity, Proliferation and Migration Rate Assessments of Human Dermal Fibroblast Adult Cells using Zingiber zerumbet Extract
Mazlyzam Abdul Latif et al.
SAINS MALAYSIANA (2019)
Combination Treatment with the BRAFV600E Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma
Ju Hye Jeong et al.
THYROID (2019)
ABT-263 exhibits apoptosis-inducing potential in oral cancer cells by targeting C/EBP-homologous protein
In-Hyoung Yang et al.
CELLULAR ONCOLOGY (2019)
Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy
Guoquan Zhu et al.
ENDOCRINE CONNECTIONS (2019)
Molecular mechanisms of estrogen receptor β-induced apoptosis and autophagy in tumors: implication for treating osteosarcoma
Zheng-ming Yang et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2019)
Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review
Zeping Han et al.
BIOMED RESEARCH INTERNATIONAL (2019)
Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia
Jarno L. Kivioja et al.
LEUKEMIA (2019)
Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction
Anna Walaszczyk et al.
AGING CELL (2019)
Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2(-/-)) mice
Anja Moncsek et al.
HEPATOLOGY (2018)
BH3 mimetics as anti-fibrotic therapy: Unleashing the mitochondrial pathway of apoptosis in myofibroblasts
Tobias Kuehl et al.
MATRIX BIOLOGY (2018)
Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin
Eun Young Lee et al.
TOXICOLOGY IN VITRO (2018)
Inhibition of Bcl-2/xl With ABT-263 Selectively Kills Senescent Type II Pneumocytes and Reverses Persistent Pulmonary Fibrosis Induced by Ionizing Radiation in Mice
Jin Pan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
David Lagares et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Cellular senescence mediates fibrotic pulmonary disease
Marissa J. Schafer et al.
NATURE COMMUNICATIONS (2017)
Transcription Factor C/eBP Homologous Protein in Health and Diseases
Yuan Yang et al.
FRONTIERS IN IMMUNOLOGY (2017)
Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer
Wataru Nakajima et al.
CANCER BIOLOGY & THERAPY (2016)
Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors
Yi Zhu et al.
AGING CELL (2016)
The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis
Daniel Karin et al.
DIFFERENTIATION (2016)
The Clinical Features and Expression of bcl-2, Cyclin D1, p53, and Proliferating Cell Nuclear Antigen in Syndromic and Nonsyndromic Keratocystic Odontogenic Tumor
Norliwati Ibrahim et al.
JOURNAL OF CRANIOFACIAL SURGERY (2016)
Gamma-tocotrienol acts as a BH3 mimetic to induce apoptosis in neuroblastoma SH-SY5Y cells
Jen-Kit Tan et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies
Andrew W. Roberts et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines
Lloyd T. Lam et al.
CANCER CELL INTERNATIONAL (2015)
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: MD Anderson Cancer Center Off Label Experience
Ramona Dadu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
Thomas J. Kipps et al.
LEUKEMIA & LYMPHOMA (2015)
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
J. D. Leverson et al.
CELL DEATH & DISEASE (2015)
A Cross Sectional Study of Cardiopulmonary Complications and Severity of Pulmonary Hypertension and Lung Fibrosis in Patients With Systemic Sclerosis
Wan Ahmad Syahril Rozli Wan Ali et al.
ARCHIVES OF RHEUMATOLOGY (2015)
The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA
Ryan Soderquist et al.
APOPTOSIS (2014)
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report
Fabiana Ostronoff et al.
BLOOD (2014)
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia
Aneel Paulus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction
Angeliki Thanasopoulou et al.
HAEMATOLOGICA (2014)
Gossypol Increases Expression of the Pro-apoptotic BH3-only Protein NOXA through a Novel Mechanism Involving Phospholipase A2, Cytoplasmic Calcium, and Endoplasmic Reticulum Stress
Ryan S. Soderquist et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur et al.
LANCET ONCOLOGY (2014)
Fibrosis-a lethal component of systemic sclerosis
Yuen Yee Ho et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Many players in BCL-2 family affairs
Tudor Moldoveanu et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Francois Vaillant et al.
CANCER CELL (2013)
Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma
Joachim C. Mertens et al.
CANCER RESEARCH (2013)
Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells
Vasileios A. Stamelos et al.
GYNECOLOGIC ONCOLOGY (2013)
Alpha-Helical Destabilization of the Bcl-2-BH4-Domain Peptide Abolishes Its Ability to Inhibit the IP3 Receptor
Giovanni Monaco et al.
PLOS ONE (2013)
Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation
Kevin B. Kim et al.
THYROID (2013)
Where Killers Meet-Permeabilization of the Outer Mitochondrial Membrane during Apoptosis
Tom Bender et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Mechanisms of Action of Bcl-2 Family Proteins
Aisha Shamas-Din et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
Delphine Merino et al.
BLOOD (2012)
Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo
S. Ackler et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin et al.
CLINICAL CANCER RESEARCH (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Navitoclax (ABT-263) Reduces Bcl-xL-Mediated Chemoresistance in Ovarian Cancer Models
Maureen Wong et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Samantha R. Oakes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Survivin expression and targeting in breast cancer
Kumkum Jha et al.
SURGICAL ONCOLOGY-OXFORD (2012)
NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern
Iris H. I. M. Hollink et al.
BLOOD (2011)
Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xL
Jue Shi et al.
CANCER RESEARCH (2011)
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
Jun Chen et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
Scott Ackler et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
Stephen K. Tahir et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models
Alex R. Shoemaker et al.
CLINICAL CANCER RESEARCH (2008)
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
Richard Lock et al.
PEDIATRIC BLOOD & CANCER (2008)
Bcl-2 family proteins are essential for platelet survival
H. Zhang et al.
CELL DEATH AND DIFFERENTIATION (2007)
Studies leading to potent, dual inhibitors of bcl-2 and Bcl-xL
Milan Bruncko et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Design, synthesis, and computational studies of inhibitors of Bcl-XL
Cheol-Min Park et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
SN Willis et al.
GENES & DEVELOPMENT (2005)
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
L Chen et al.
MOLECULAR CELL (2005)
Structural biology of the Bcl-2 family of proteins
AM Petros et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2004)
Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion
M Kawatani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
分享论文
